<DOC>
	<DOCNO>NCT02479880</DOCNO>
	<brief_summary>To characterize long term ( ie , 96 week follow ) bone safety profile open-label tenofovir disoproxil fumarate ( tenofovir DF ) treatment CHB-infected adolescent . This include prospectively evaluate compare bone mineral density ( BMD ) change CHB-infected adolescent 12 &lt; 18 year age treat tenofovir DF European treatment center assign one two schedule renal bone laboratory monitoring BMD measurement .</brief_summary>
	<brief_title>Utilization Efficacy Tenofovir DF Adolescents With Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . 12 &lt; 16 year age 2 . Documented chronic hepatitis B virus ( HBV ) infection 3 . Weight â‰¥ 35 kg 4 . Able swallow oral tablet 5 . Negative pregnancy test female childbearing potential 6 . Adequate kidney ( renal ) function 7 . Parent legal guardian potential study subject able provide write informed consent 1 . Previously receive tenofovir DF 2 . Sexuallyactive male female reproductive potential willing use effective method contraception study 3 . Females pregnant breastfeeding , females wish become pregnant course study 4 . Known hypersensitivity tenofovir DF , metabolites formulation excipients 5 . Any condition ( include alcohol substance abuse ) prior therapy , opinion Investigator , would make subject unsuitable study unable comply treatment requirement</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>